



KERRY

Preliminary Statement of Results 2005



the science of food



- Review of Business Hugh Friel
 - Financial Review Brian Mehigan
 - Business Growth Prospects Hugh Friel
 - Q&A
- 

2005 Performance: Key Accomplishments



- Good top-line and earnings growth
 - Alignment of business structures to changing marketplace
 - Portfolio optimisation
 - Accelerated innovation programme
 - Sustainable platform for profitable growth
 - Consistent strategy delivering good results - outperforming competitors
- 
- A decorative horizontal bar at the bottom of the slide, consisting of a light blue gradient that tapers from left to right.

2005 Results



- Revenue €4.4bn - growth of 7%
- Trading profit growth of 7% to €380m
- Trading margin maintained at 8.6%
- Profit after tax up 16% to €236m
- Adjusted EPS* up 7.1% to 131.6 cent
- Final dividend per share up 15.8% to 11 cent
- Free cash flow of €248m
- R&D expenditure increased to €125m

*Note: * before intangible amortisation and non-trading items*

Kerry: *Ingredients' and Foods' Positioning*



Ingredients

ASI's - World leader in Application Specific Ingredients

Bio-Science - Key bio-ingredients and pharma technologies 'Linking food and pharma'

Mastertaste - Building a global flavour business

Foods

Chilled convenience - leading brands
Customer brands - growth categories



Business Review - *Ingredients 2005*



	2005	Total Growth
Revenue	€3,022m	+9%
Trading Profit	€284m	+9%

- Good H2
- Outperformed the market
- Accelerated rate of new product development
- Improvement in cost recovery
- Mastertaste consolidation phase completed
- Progress in leveraging Bio-Science technologies
- Strong pharma pipeline

Growth Plan: Ingredients



- Leveraging nutrition focus through broad customer base
- Exploiting unrivalled technology portfolio to deliver wellness, convenience solutions
- New formulations / delivery systems for changing marketplace
- Increased contribution from emerging growth markets (Asia, Eastern Europe, South America)



2005 Issues: Business re-alignment to address marketplace changes

Growth Plan: Bio-Science



- Successful first year post acquisition
- Restructuring operations and market representation
- Investment in new technical facilities and business headquarters
- Establishment of Group Nutrition Technical Centre
- Leverage pharma and bio-ingredients science-based technical capabilities



2005 Issues: Bio-Science business structuring and 'unlocking' of technologies

Growth Plan: Flavours



- Integration of Manheimer, Flavurence and Fructamine
- Consolidation of Flavours, Natural Products and Fragrance strategies
- Strong innovation through
 - 'Chef Style' clean label flavours
 - Zesti® anti-microbial factor
 - Steromulsion functional flavours
 - Unique Crystals® freeze-dried natural extracts
 - Herbal / botanical extracts



2005 Issues: Mastertaste business platform consolidation for global development

Business Review - *Consumer Foods 2005*



	2005	Total Growth
Revenue	€1,726m	+4%
Trading Profit	€123m	+4%

- Competitive retail environment
- Brands performing strongly
- Significant drop in frozen prepared meals
- Slow down in chilled ready meals in H2
- Small % p.a. inflation in food required
- Investment in premium growth categories
- Acquisition of Noon

Growth Plan: Consumer Foods



- Continued investment in leading brand positions
- Nutrition + convenience focus
- Growth in brand shares and niche markets through premiumisation
- 'Food-to-go' - innovative offerings
- Business restructuring and investment in premium categories



2005 Issues: Downturn in chilled ready meals growth in H2 and decline in frozen sector



Financial Review




2005 Financial Highlights



Revenue	→	€4,430m	+7.3%
Trading profit	→	€380m	+6.9%
Adjusted EPS*	→	131.6 cent	+7.1%
Basic EPS	→	126.1 cent	+15.2%
Free cash flow	→	€248m	2004: €291m
Acquisition programme	→	€238m	2004: €712m

Note: * before intangible amortisation and non-trading items

Revenue Analysis



Note: Like-for-like represents revenue growth before subsidiary translation and acquisitions / disposals impact

2005 Revenue Growth by Business




Like-for-like

	2005	2004	2003
Ingredients	5%	5%	5%
Consumer Foods	2%	2%	4%
Group	4%	4%	5%

Like-for-like trend robust

Note: Like-for-like represents revenue growth before subsidiary translation and acquisitions / disposals impact

2005 Revenue Growth by Destination




All territories growing

Note: Like-for-like represents revenue growth before subsidiary translation and acquisitions / disposals impact

Revenue Growth Components



Like-for-like % Growth



Like-for-like % Growth

	2005	2004
Volume	4%	4%
Price	1%	1%
Trading currency	(1%)	(1%)
Group	4%	4%

Solid underlying performance

Note: Like-for-like represents revenue growth before subsidiary translation and acquisitions / disposals impact

Trading Margin Trend




	2005	2004	2003	2002
Ingredients	9.4%	9.4%	9.1%	9.0%
Consumer Foods	7.1%	7.1%	7.1%	6.7%
Group	8.6%	8.6%	8.4%	8.1%

Trend solid in 2005

*Note: * numbers for 2002 and 2003 are pre IFRS*

Trading Margin Progression



Issues managed



Five Year Free Cash Flow



	2005	2004	2003	2002	2001
	€m	€m	€m	€m	€m
EBITDA*	482	447	392	390	331
Movement in working capital	1	35	8	46	(34)
Capital expenditure (net)	(120)	(91)	(93)	(92)	(89)
Interest	(64)	(46)	(41)	(50)	(46)
Taxation	(51)	(54)	(40)	(43)	(44)
Free Cash Flow	248	291	226	251	118

> €200m again in 2005

Note: * before intangible amortisation and non-trading items

Financial Ratios



	2005	2004
Debt : Equity	75%	77%
Debt : Market capitalisation	37%	35%
EBITDA : Net interest*	8.0x	9.3x
Debt : EBITDA*	2.6x	2.6x

Debt : EBITDA < 3.5x

*Note: * ratios calculated in accordance with financial covenants*

Return on Investment



	2005	2004	2003	2002	2001
ROAE*	15.2%	15.5%	15.2%	15.2%	14.8%
ROACE*	11.1%	11.6%	11.4%	11.6%	11.8%
CFROI	11.0%	13.9%	12.5%	14.6%	9.6%

ROAE > 15%

*Note: * before non-trading items*

Non-trading Items



- Impact of non-trading items is break-even after tax in 2005
 - €14.7m profit from disposal of non current assets
 - €18.3m loss from disposal of businesses and plant closures
 - €3.7m tax credit relating to non-trading items
- Continuing programme of business and plant rationalisation mainly in relation to European ingredient and consumer food businesses

Zero net impact in 2005

Other Financial Matters



- Finance costs Up €16.5m year-on-year due to impact of acquisitions, rate increases and pension costs offset by cash flow impact
- Taxation Tax charge on continuing operations down to 22% due to post acquisition integration
- IFRS First full year reporting under IFRS. New goodwill, deferred tax and pension policies adopted but no significant impact on adjusted EPS or free cash flow
- Pensions Pension charge for the year amounted to €42m and the net deficit after tax amounted to €179m


Interest rates up, tax rates down



Outlook 2006 and Future Prospects




EPS* Growth (cent)



Note: numbers for 1996 to 2003 are pre IFRS

*Note: * before intangible amortisation and non-trading items*

Food Industry 2006: Onwards



Ingredients, Flavours and Bio-Science Positioned to Address Multiple Nutritional Platforms



	Nutritional Platform	Platform Description	Comments
I&M →	Medical & Clinical Recovery	Post Trauma Hydration, Enteral Feeding Applications, etc	↑ Increasing Technical Input
	Infant and Child Development	Infant Development, Targeted Child Life Stage Nutrition	
FF →	Condition-specific Dietary Fortification	Targeted Enrichment (Respiratory, Cardiovascular, Diabetic, Specific Cancer, Arthritis / Joint Health, Obesity, Depression / Anxiety, Menopause, Ageing)	
	Sports Performance Enhancement	Athletic Performance / Recovery Enhancement	
	Energy Enhancement	Quick or Sustained Energy Benefit	
	Inherently Healthy Alternatives	Perceived Natural and Organic Benefits “good for you” whole foods (e.g. Oatmeal, Soy)	
	Weight Management	Weight Loss Mechanisms	
MAIN-STREAM →	Condition-specific Dietary Reduction	Reduction of “bad for you” Elements (Fat, Calories, Trans-fats, Sodium, etc.)	
	Mainstream (Market Standard) Products	Mainstream (Market Standard) Products	

Outlook for 2006




- Ingredients, Bio-Science, Flavours and Foods - well focused, solid business platforms
- Nutritional focus - leverage Group's range of technologies and expertise
- Strong Bio-Science project and product pipeline
- Focus on Foods' brands and premiumisation
- Recovery in ready meal growth categories
- Acquisitions
- Continued development in emerging markets



Confident of meeting market growth expectations

Kerry Group - *Medium Term Prospects*



- Robust, solid, broad based business with good market positions
 - Good people, quality assets, strong financial base
 - Significant organic growth potential, exploiting Group's science platforms through broad customer base
 - Innovation focused on nutritional offerings and therapeutics
 - Progressive business development programmes in Asia, Eastern Europe and South America
 - On-going industry consolidation - acquisition opportunities
 - Delivering solid revenue and earnings growth
- 
- A decorative horizontal bar at the bottom of the slide, featuring a light blue gradient that transitions from a solid light blue on the left to a slightly darker shade on the right.



Additional Information



Business Review - *Ingredients Europe 2005*



Europe	2005	Total Growth	Like-for-like
Revenue*	€1,264m	+9%	+5%

- Excellent performance
- Plants in 9 countries and divisional sales offices in other markets
- Investments in Almere, Wittstock, York, Menstrie
- Consolidation of Ingredients, Bio-Science and Mastertaste platforms
- Breadth of products, customer listing and geographic spread
- Eastern European markets growing

*Note: * revenue by location of customers*

Business Review - *Ingredients Americas*



Americas	2005	Total Growth	Like-for-like
Revenue*	€1,213m	+8%	+4%

- North and South America
- Ingredients, Bio-Science and Flavours
- Time lag in overcoming cost/price squeeze
- NPD regained momentum
- Refocusing to meet diverse consumer requirements
- Progress in sweet, seasonings and beverages
- Encouraging results in cell nutrition and Bio-Science excipients

*Note: * revenue by location of customers*

Business Review - *Ingredients Asia Pacific*



Asia Pacific	2005	Total Growth	Like-for-like
Revenue*	€332m	+16%	+7%

- Manufacturing in 7 countries
- 13 sales offices
- Continuing to build management team
- Significant growth opportunities
- Nutrition, flavours and foodservice
- China investment programme commenced

*Note: * revenue by location of customers*

EPS Reconciliation




2004 € cent		2005 € cent	Growth %
122.9	Adjusted EPS*	131.6	7.1%
(5.3)	Intangible amortisation	(5.5)	
(8.1)	Non-trading items (net of tax)	0.0	
109.5	Basic EPS	126.1	15.2%

Note: * before intangible amortisation and non-trading items


- Reporting currency translation impact
 - No major change in dollar and sterling translation rates
- Trading currency transaction impact on trading profit
 - Rate differential costing €44m across the last two years
- Balance sheet - assets and liabilities substantially matched

Euro - US Dollar Trend



	2005	2004
Avg Fx Rate	1.24	1.25
% Change	0.8%	

Euro - Sterling Trend



	2005	2004
Avg Fx Rate	0.68	0.68
% Change	0%	

Cash Flow (€m)



	2005	2004
Cash from operations	483	482
Finance and taxation	(115)	(100)
Capital expenditure (net)	(120)	(91)
Free cash flow	248	291
Acquisitions and disposals		
- Businesses acquired	(246)	(727)
- Businesses sold	3	-
- Non-trading items	(15)	(17)
	(258)	(744)
Equity dividends paid	(27)	(24)
Financing - issue of share capital	4	10
	(33)	(467)
Exchange adjustment on net debt	(105)	35
Increase in borrowings	(138)	(432)
Opening net debt	(1,137)	(705)
Closing net debt	(1,275)	(1,137)

Debt Profile (€m)



	Net Borrowings	@ Floating Rates	@ Fixed Rates
Euro	418	418	-
Sterling	275	275	-
US Dollar	471	420	51
Others	111	111	-
	1,275	1,224	51
	100%	96%	4%


Weighted average period for which rate is fixed: 2.6 years

Maturity Profile of Net Debt



	31 Dec 2005 €m	31 Dec 2004 €m
Within one year	(22)	(1)
Between 1 and 2 years	136	176
Between 2 and 5 years	702	432
Between 5 and 10 years	459	294
After 10 years	-	236
	<u>1,275</u>	<u>1,137</u>
Weighted average maturity in years:	5.1	5.4

R&D Expenditure



Note: * figures relate to R&D as a percentage of revenue

EPS Broker Estimates 2006




	2006 EPS*	%
	€ Cent	Growth
Consensus	141.1	7.2
Davy	140.4	6.7
ABN Amro	140.4	6.7
Goodbody	140.8	7.0
Soc Gen	143.0	8.7
NCB	140.8	7.0
Merrion	141.1	7.2

Consensus +7.2%

*Note: * before intangible amortisation and non-trading items*

Shareholder Analysis



Shares in issue: 187 million

KERRY



the science of food